Latest DNA vaccination Stories

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today it has received a contract for $933,000 from the Department of Defense (US Army) to continue research and development of DNA-based vaccines delivered via its proprietary electroporation system. The contract, titled "Design and Engineering of the Elgen Gene Delivery System for Screening and Validation of Vaccine Candidates of Military...

Inovio Biomedical has achieved positive results from its proprietary R&D program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology. The preclinical study results showed that in mice with metastatic melanoma treated with a DNA-based therapeutic vaccine via intramuscular delivery, six of eight (75%) were tumor-free at the conclusion of the study. Inovio's R&D program is assessing multiple DNA vaccine candidates against infectious...

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that it achieved positive results from its proprietary research and development program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology. The pre-clinical study results showed that in mice with metastatic melanoma treated with a DNA-based therapeutic vaccine via intramuscular delivery,...

PURCHASE, N.Y., Sept. 9 /PRNewswire/ -- A recently completed study from researchers at Colorado State University supported by the Division of Vector-Borne Infectious Diseases with the Centers for Disease Control and Prevention (CDC) has demonstrated that AHCC(R) (Active Hexose Correlated Compound) enhances host resistance by boosting protective immune responses specific to the West Nile Virus. Since its discovery in the United States in 1999, infections caused by the West Nile Virus have...

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that results from nonhuman primate studies of a Vaxfectin(R)-formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising approach to the development of a measles vaccine to address an unmet need for human infants. Vical recently reported breakthrough preliminary Phase 1 trial results for the company's H5N1 pandemic influenza DNA vaccines formulated...

Vical has announced a research collaboration with the Karolinska Institute, a European medical university, and the Swedish Institute for Infectious Disease Control, a governmental expert agency, to evaluate the company's Vaxfectin adjuvant with the Biojector 2000 needle-free injection system for a multivalent preventive DNA vaccine against HIV. The Karolinska Institute has completed a 38-subject Phase I trial testing a prime-boost HIV vaccine regimen using three doses of unadjuvanted DNA...

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated today announced a research collaboration with the Karolinska Institute, a leading European medical university, and the Swedish Institute for Infectious Disease Control (SMI), a governmental expert agency, to evaluate Vical's Vaxfectin(R) adjuvant with the Biojector(R) 2000 needle-free injection system (Bioject Medical Technologies Inc., OTCBB:BJCT) for a multivalent preventive DNA vaccine against HIV. Professor Eric Sandstrom,...

Inovio Biomedical has expanded its research license with the International AIDS Vaccine Initiative, an organization dedicated to ensuring the development of safe and effective preventive HIV vaccines. Inovio and International AIDS Vaccine Initiative (IAVI) signed an initial agreement in March 2007. The parties have now extended this agreement by three years. As part of this new agreement, Inovio will provide IAVI with additional proprietary electroporation devices to conduct preclinical...

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to ensuring the development of safe and effective preventive HIV vaccines. Inovio's electroporation delivery technology is intended to enhance the potency of DNA vaccines against cancers and...

Inovio Biomedical Corporation (AMEX: INO) ("Inovio") today reported financial results for the three and six months ended June 30, 2008. Total revenue for the three and six months ended June 30, 2008 was $663,000 and $1.3 million, respectively, as compared to $496,000 and $999,000, respectively, for the same periods in 2007. Revenue consisted of license fees, milestone payments, revenue recognized from collaborative research and development arrangements and grants. Total operating...